FDA Approves Teva's Monthly Schizophrenia Shot
Teva announced FDA approval for Weltruza, a monthly schizophrenia injection using Medincell's technology. This is Teva's second approval from its partnership with Medincell, following Uzedy in 2023. Medincell could earn up to $112 million in milestones plus royalties. Teva shares rose 2% in Tel Aviv.
How this was made
The 30-second read
Why it matters
The approval creates a new revenue stream for Teva and milestone payments for Medincell, prompting a modest share rally.
Market read
Regulatory clearance for a novel schizophrenia treatment drives short‑term upside for Teva and highlights sector momentum.
What to watch
Potential reimbursement challenges and competition from existing long‑acting risperidone products.
Background
Teva's partnership with Medincell yields a new olanzapine long‑acting injectable, Weltruza, approved by the FDA.
Ticker impact
FDA approved Teva's once‑a‑month schizophrenia injection Weltruza, triggering a 2% share rise.
upward pressure as the market prices in the FDA approval and upcoming royalty stream.
Regulatory clearance is a primary catalyst; the share price already rose 2% on the news.
Market effects
Adds competitive pressure in the long‑acting antipsychotic market, may spur other firms to accelerate pipelines.
Positive for US pharma sector; modest effect on broader market.
Limited to psychiatric drug space, but highlights FDA's role in accelerating novel formulations.
Counterpoint
Milestone payments are contingent; if sales lag, the upside could be limited.
Key entities
- CompanyTeva Pharmaceutical Industries
US‑listed pharmaceutical company receiving FDA approval.
- CompanyMedincell
Partner providing the injectable technology, not US‑listed.
